BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET
BridgeBio Pharma (Nasdaq: BBIO), a biopharmaceutical company specializing in genetic diseases, has scheduled its first quarter 2025 financial results conference call for Tuesday, April 29, 2025, at 4:30 pm ET. The company will release its Q1 financial results and program updates after market close on the same day.
Investors and interested parties can access the live webcast through the 'Events' page in the Investors section of BridgeBio's website. A replay will remain available for 30 days following the event. Registration for the webcast is available through a dedicated online link.
BridgeBio Pharma (Nasdaq: BBIO), un'azienda biofarmaceutica specializzata in malattie genetiche, ha programmato la conference call per la presentazione dei risultati finanziari del primo trimestre 2025 per martedì 29 aprile 2025, alle 16:30 ET. La società pubblicherà i risultati finanziari del Q1 e gli aggiornamenti sui programmi dopo la chiusura del mercato lo stesso giorno.
Investitori e interessati potranno seguire la diretta streaming tramite la pagina "Eventi" nella sezione Investitori del sito web di BridgeBio. La registrazione della diretta resterà disponibile per 30 giorni dopo l'evento. La registrazione per il webcast è accessibile tramite un link online dedicato.
BridgeBio Pharma (Nasdaq: BBIO), una compañía biofarmacéutica especializada en enfermedades genéticas, ha programado su conferencia telefónica sobre resultados financieros del primer trimestre de 2025 para el martes 29 de abril de 2025 a las 4:30 pm ET. La empresa publicará sus resultados financieros del primer trimestre y actualizaciones de programas después del cierre del mercado ese mismo día.
Inversionistas y personas interesadas podrán acceder a la transmisión en vivo a través de la página de "Eventos" en la sección de Inversionistas del sitio web de BridgeBio. La repetición estará disponible durante 30 días después del evento. La inscripción para el webcast está disponible mediante un enlace en línea dedicado.
BridgeBio Pharma (나스닥: BBIO)는 유전 질환을 전문으로 하는 바이오제약 회사로, 2025년 1분기 재무실적 컨퍼런스 콜을 2025년 4월 29일 화요일 오후 4시 30분(동부시간)에 예정하고 있습니다. 회사는 같은 날 시장 마감 후 1분기 재무실적과 프로그램 업데이트를 발표할 예정입니다.
투자자 및 관심 있는 분들은 BridgeBio 웹사이트 투자자 섹션의 '이벤트' 페이지를 통해 생중계 웹캐스트에 접속할 수 있습니다. 이벤트 종료 후 30일간 다시보기 서비스가 제공됩니다. 웹캐스트 등록은 전용 온라인 링크를 통해 가능합니다.
BridgeBio Pharma (Nasdaq : BBIO), une société biopharmaceutique spécialisée dans les maladies génétiques, a programmé sa conférence téléphonique sur les résultats financiers du premier trimestre 2025 pour le mardi 29 avril 2025 à 16h30 ET. La société publiera ses résultats financiers du premier trimestre ainsi que les mises à jour des programmes après la clôture des marchés le même jour.
Les investisseurs et parties intéressées pourront accéder à la diffusion en direct via la page « Événements » de la section Investisseurs du site web de BridgeBio. Le replay restera disponible pendant 30 jours après l’événement. L’inscription au webcast est possible via un lien en ligne dédié.
BridgeBio Pharma (Nasdaq: BBIO), ein biopharmazeutisches Unternehmen, das sich auf genetische Erkrankungen spezialisiert hat, hat seine Telefonkonferenz zu den Finanzergebnissen des ersten Quartals 2025 für Dienstag, den 29. April 2025, um 16:30 Uhr ET angesetzt. Das Unternehmen wird die Finanzergebnisse des ersten Quartals und Programm-Updates am selben Tag nach Börsenschluss veröffentlichen.
Investoren und Interessierte können den Live-Webcast über die Seite "Veranstaltungen" im Investor-Bereich der BridgeBio-Website verfolgen. Eine Aufzeichnung ist 30 Tage nach der Veranstaltung verfügbar. Die Anmeldung zum Webcast ist über einen speziellen Online-Link möglich.
- None.
- None.
PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its first quarter financial results and program updates after the market closes on Tuesday, April 29, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day.
To access the live webcast of BridgeBio’s presentation, please visit the “Events” page within the Investors section of the BridgeBio website at https://investor.bridgebio.com/news-and-events/event-calendar. A replay of the webcast will be available on the BridgeBio website for 30 days following the event.
Participants may access the webcast by registering online using the following link, https://events.q4inc.com/attendee/682276610.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter and Facebook.
BridgeBio Contact:
Bubba Murarka, EVP Communications
contact@bridgebio.com
(650)-789-8220
Chinmay Shukla, VP Strategic Finance
IR@bridgebio.com
FAQ
When will BridgeBio (BBIO) release its Q1 2025 earnings?
How can I access BridgeBio's (BBIO) Q1 2025 earnings call?
How long will BridgeBio's (BBIO) Q1 2025 earnings call replay be available?
What time is BridgeBio's (BBIO) Q1 2025 earnings conference call?
